Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5435_Библиотеки_им_академика_М_И_Перельмана
.pdf
ability to reproduce and validate findings depends on the completeness and accu-
racy of deposited data.
4. Comparative analysis: Validating structural models often involves comparing
them to other experimental data or existing knowledge. Researchers use tools
like distance-matrix alignment to compare protein structures and identify struc-
tural homologs. This helps assess the consistency of the model with known pro-
tein folds and functions [136].
By addressing these issues through rigorous experimental techniques, careful model
building, validation statistics, and comparative analyses, researchers enhance the
credibility and impact of their structural studies [137].
Addressing data quality and validation issues in structural biology requires a
combination of experimental approaches, computational tools, and rigorous method-
ologies. Here’s how these challenges can be addressed.
11.14.3 Data quality solutions
1. Improved experimental techniques: Advancements in experimental techniques,
such as cryo-EM and X-ray crystallography, have led to higher resolution struc-
tures and reduced artifacts. Continuous development of instrumentation and
data collection methods helps improve data quality.
2. Data preprocessing: Rigorous preprocessing of raw data is crucial to remove
noise, correct for artifacts, and enhance the signal-to-noise ratio. This includes
procedures like image alignment, radiation damage correction, and motion
correction in cryo-EM.
3. Advanced data analysis: Utilizing advanced computational algorithms and statisti-
cal methods can help extract accurate information from noisy data. Techniques
like maximum likelihood estimation or Bayesian approaches improve data inter-
pretation [138, 139].
11.14.4 Data validation solutions
1. Validation software: Dedicated software tools, such as MolProbity, Phenix, and Coot,
provide comprehensive validation metrics for structural models. These tools assess
factors like geometry, bond lengths, and steric clashes to ensure model quality.
2. Cross-validation: Cross-validation involves dividing data into training and valida-
tion sets. In structural biology, this can include refining one part of the data and
then comparing it with the remaining part to ensure consistency and reliability.
264 Anuradha Mehra et al.
https://t.me/med1917
3. Benchmarking: Comparing newly determined structures to known structures or
biochemical data helps validate findings. This can involve analyzing the fit of ex-
perimental maps, identifying conserved residues, or assessing structural motifs.
4. Independent replication: Reproducing structural results using different experi-
mental techniques or in different laboratories helps verify the accuracy of the
findings. This can involve solving the same structure using multiple methods or
validating a model’s predictions through functional assays.
5. Peer review and community validation: Submitting structures to rigorous peer re-
view ensures that the methods, data, and interpretations are thoroughly scruti-
nized by experts. Community efforts like CASP involve blind tests to assess the
accuracy of structural predictions.
6. Data deposition standards: Adhering to standardized data deposition practices, as
outlined by organizations like the PDB, ensures that high-quality data and valida-
tion metrics are available for public scrutiny.
7. Educational initiatives: Training programs and workshops that focus on data
quality and validation techniques help researchers develop the skills needed to
critically assess and validate their own structural work.
By combining these solutions, structural biologists can ensure that their findings are
robust, accurate, and reliable. Rigorous data collection, thorough validation, and ad-
herence to best practices enhance the overall quality of structural biology research
and contribute to meaningful advancements in our understanding of biological mac-
romolecules and their functions [140, 141].
11.15 Overcoming challenges in protein
crystallization and sample preparation
11.15.1 Protein crystallization
Screening conditions: Many proteins have complex structural requirements for crys-
tallization. For example, G protein-coupled receptors are notoriously challenging to
crystallize due to their flexibility and amphipathic nature. To overcome this chal-
lenge, researchers employ extensive crystallization screens with hundreds of condi-
tions, searching for the optimal parameters that promote crystal formation [142].
Additives and ligands: In fundamental membrane proteins, such as bacteriorhodopsin,
inclusion of detergents or lipids can enhance stability and facilitate crystal growth.
These additives mimic the natural lipid bilayer environment, increasing the chances of
successful crystallization.
11 Role of structural genomics in drug discovery 265
https://t.me/med1917
Seeding: Seeding was crucial in obtaining high-resolution crystals of insulin. The ini-
tial crystallization attempts yielded poorly diffracting crystals. However, seeding with
small insulin crystals provided the necessary nucleation sites for larger, well-ordered
crystals to grow [143].
Macromolecular crowding: The protein chaperone GroEL was challenging to crystal-
lize due to its flexibility. Researchers used macromolecular crowding with polyethyl-
ene glycol to enhance the crystallization of GroEL by stabilizing its conformation and
reducing solvent-exposed surfaces [144].
Temperature gradient methods: Hen egg-white lysozyme crystallization is an example
where temperature gradients improved crystallization. By creating a temperature
gradient, the crystallization drops experiences changes in solubility, leading to the
formation of well-ordered crystals [145].
11.15.2 Sample preparation
Purification optimization: The small GTPase Ras was challenging to crystallize due to
its intrinsic instability. Researchers used a combination of site-directed mutagenesis
and optimized purification protocols to obtain well-diffracting crystals [146].
Protein concentration: The human protein p53 is known for its aggregation propen-
sity. Optimizing protein concentration and using aggregation inhibitors helped re-
searchers obtain crystals suitable for X-ray diffraction studies [147].
Buffer and pH: The challenge of crystallizing the enzyme lysozyme was overcome by
systematically exploring different buffers and pH conditions. The addition of organic
solvents and polyethylene glycol contributed to successful crystallization.
Posttranslational modifications: Insulin, a protein with posttranslational modifica-
tions, required careful consideration of glycosylation for successful crystallization. By
engineering the protein to remove glycosylation sites, researchers improved crystalli-
zation success [148].
Dealing with flexible regions: The protein Bcl-xL has flexible loops that hindered crys-
tallization. Researchers used limited proteolysis to remove these loops, resu lting in
improved crystallization conditions.
Surface entropy reduction: Crystallizing the enzyme ketosteroid isomerase involved
reducing surface entropy through mutagenesis. This modification helped decrease the
protein’s flexibility and improved crystallization outcomes [149].
Conformational stabilization: For the protein T4 lysozyme, introducing point muta-
tions that stabilized specific conformations facilitated the crystallization process.
266 Anuradha Mehra et al.
https://t.me/med1917
These mutations enhanced the rigidity of the protein and increased the likelihood of
crystal formation.
Alternative crystallization techniques: The growth hormone somatotropin posed chal-
lenges due to its intrinsic flexibility. Researchers used counter-diffusion techniques,
where the protein diffused against a precipitant solution, leading to improved crystal
quality [150].
The challenges of protein crystallization and sample preparation are diverse and often
specific to individual proteins. Researchers employ a combination of methods, ranging
from screening conditions and using additives to protein engineering and alternative
crystallization techniques, to overcome these challenges. Understanding the unique
properties and requirements of each protein, coupled with systematic optimization, is
essential for successful protein crystallization (Table 11.1) and obtaining high-quality
crystals for structural analysis [151].
Table 11.1: The different structural genomics approaches.
Aspect Challenges Solutions Examples Reasons
Protein crystallization
Screening
conditions
Complex
requirements,
variability
High-
throughput
screening
methods
GPCRs,
membrane
proteins
Proteins have specific
physicochemical preferences
for crystallization conditions.
Additives and
ligands
Amphipathic
proteins,
stability issues
Use of
detergents,
lipids,
stabilizers
Bacteriorhodopsin Mimic native environment,
enhance stability, and facilitate
crystal growth.
Seeding Poor
nucleation,
low-quality
crystals
Introduce seed
crystals,
templating
Insulin Seed crystals provide a
template for crystal growth,
overcoming nucleation
challenges.
Macromolecular
crowding
Flexible
proteins,
unstable
conformers
Introduce inert
macromolecules
GroEL Crowding stabilizes
conformations, reduces surface
area, and promotes crystal
growth.
Temperature
gradient
Suboptimal
nucleation
and growth
Create
temperature
gradients
Hen egg-white
lysozyme
Temperature gradients
influence solubility and
promote crystal formation.
11 Role of structural genomics in drug discovery 267
https://t.me/med1917
11.16 Integrating structural data with other
genomic technologies
Incorporating structural information into genomic technologies proves to be a robust
strategy that enriches our comprehension of protein functionality, interactions, and
their involvement in diverse biological processes. This amalgamation can yield valu-
able insights into the intricate molecular mechanisms driving diseases and can offer
Table 11.1 (continued)
Aspect Challenges Solutions Examples Reasons
Sample
preparation
Purification
optimization
Impurities,
instability
Optimize
purification
protocols
Ras Purity impacts crystallization
quality, stability is crucial for
successful crystallization.
Protein
concentration
Aggregation,
weak
diffraction
Precise
concentration
determination
p Balance between aggregation
and diffraction quality is critical.
Buffer and pH Denaturation,
solubility
issues
Systematic
testing of
buffers, pH
Lysozyme Buffer choice affects protein
stability, solubility, and crystal
formation.
Posttranslational
mods
Altered
stability,
flexibility
Engineering to
remove
modifications
Insulin Modifications affect protein
properties, engineering may
improve crystallizability.
Dealing with
flexibility
Crystal
disorder,
weak
diffraction
Limited
proteolysis,
truncation
Bcl-xL Flexible regions hinder crystal
formation, removal improves
crystallization prospects.
Surface entropy
reduction
Surface
flexibility,
aggregation
Mutations to
reduce surface
entropy
Ketosteroid
isomerase
Reduced flexibility enhances
crystallization propensity by
minimizing entropic effects.
Conformational
stabilization
Dynamic
structures,
flexibility
Protein
engineering,
ligand binding
T lysozyme Stabilization reduces flexibility,
enhancing the likelihood of
crystal formation.
Alternative
techniques
No crystal
growth,
complex
proteins
Microbatch,
counter-
diffusion, vapor
Somatotropin Alternative methods exploit
unique conditions to promote
crystal growth.
268 Anuradha Mehra et al.
https://t.me/med1917
valuable guidance for the pursuit of drug discovery. Here’s an elaboration and a tabu-
lar representation with case studies:
Methods in structural biology, such as NMR spectroscopy, X-ray crystallography,
and cryo-EM, offer comprehensive insights into the three-dimensional configurations
of proteins and macromolecular assemblies [152, 153]. However, these structural in-
sights gain greater significance when combined with other genomics technologies:
Proteomics: Integrating structural data with proteomics allows for quantification
and identification of proteins present in a parti cular sample. This can help confirm
the presence of structurally characterized proteins in complex cellular environments
and shed light on their interactions.
Genomics: Genomics data provide information about the genetic makeup and varia-
tions in different organisms. By correlating structural information with genetic muta-
tions or polymorphisms, researchers can understand how genetic changes impact
protein structure, function, and disease susceptibility.
Transcriptomics: Transcriptomics data offer insights into gene expression levels. In-
tegrating this information with structural data can help identify structural changes in
proteins under different conditions, providing a deeper understanding of their func-
tional regulation.
Metabolomics: Metabolomics provides information about the small molecule metab-
olites present in a biological system. Integration with structural data can reveal how
proteins interact with metabolites, offering insights into metabolic pathways and po-
tential drug targets.
Bioinformatics: Computational tools and algorithms can predict the effects of muta-
tions on protein structures. Integrating structural and bioinformatics data helps prior-
itize disease-associated mutations and aids in drug target identification [161, 162].
Here’s a table 11.2 that summarizes various genomic techniques, their advantages, dis-
advantages, and challenges:
11 Role of structural genomics in drug discovery 269
https://t.me/med1917
Table 11.2: Advantages, disadvantages, and challenges of various genomic techniques.
Genomic technique Advantages Disadvantages Challenges References
Whole-genome
sequencing (WGS)
Provides
comprehensive view
of an individual’s
entire genome.
Identifies both coding
and noncoding
variants.
Generates vast
amounts of data,
requiring significant
computational
resources. Can include
variants of unknown
significance.
Data storage and
analysis
complexities.
Ethical and privacy
considerations.
[]
Whole-exome
sequencing (WES)
Focuses on protein-
coding regions,
reducing data
volume.
Identifies mutations
in known disease-
associated genes.
Misses noncoding
variants and
regulatory elements.
May not cover all
relevant genes.
Identifying causal
variants in complex
diseases.
Interpretation of
variants of unknown
significance.
[]
RNA sequencing
(RNA-Seq)
Quantifies gene
expression levels.
Identifies alternative
splicing and novel
transcripts.
Limited to known
transcripts.
Requires RNA
isolation and
sequencing library
preparation.
Normalization and
batch effects in
expression data.
Data analysis for
pathway and
network analysis.
[]
Chromatin
immunoprecipitation
(ChIP-Seq)
Maps protein–DNA
interactions, such as
transcription factor
binding. Identifies
histone modifications.
Requires specific
antibodies for
immunoprecipitation.
May result in non-
specific binding.
Reproducibility and
standardization of
protocols.
Data analysis for
peak calling and
motif discovery.
[]
Assay for
transposase-
accessible chromatin
(ATAC-Seq)
Maps open chromatin
regions and DNA
accessibility.
May suffer from DNA
fragmentation bias.
Requires careful
optimization of
enzymatic reactions.
Data normalization
and comparison
between samples.
Integration with
gene expression
data.
[]
Hi-C (chromosome
conformation
capture)
Reveals D chromatin
interactions and
spatial organization.
Identifies
topologically
associated domains
(TADs).
Requires crosslinking
and complex library
preparation.
Biases in interaction
detection and
resolution.
Data processing for
interaction calling
and visualization.
Biological
interpretation of D
genome data.
[]
270 Anuradha Mehra et al.
https://t.me/med1917
11.17 Future prospects and emerging trends
The future prospects and emerging trends of genomics in drug discovery are poised
to revolutionize the field by offering unprecedented insights and opportunities. Preci-
sion medicine and targeted therapies are on the horizon, leveraging genomic informa-
tion to develop treatments tailored to individual genetic profiles, optimizing efficacy,
and minimizing side effects. The advent of genome editing technologies, notably
CRISPR-Cas9, promises to reshape drug discovery by enabling precise genetic modifi-
cations for disease modeling, target validation, and even potential therapeutic inter-
ventions. Functional genomics techniques, such as CRISPR-based screens and RNA
interference, will continue to unravel the complexities of gene functions, unveiling
new drug targets and pathways [163, 164].
The incorporation of multiomics data, merging genomics with other -omics fields
such as proteomics and metabolomics, is poised to offer a thorough comprehension of
biological systems. This will generate fres h perspectives on disease mechanisms and
reactions to drugs. Pharmacogenomics, a rapidly evolving field, offers the prospect of
predicting individual responses to drugs based on genetic variations, optimizing treat-
ment outcomes, and minimizing adverse reactions. Noncoding regions of the genome,
once considered silent, are now garnering attention, with efforts directed toward un-
raveling their regulatory roles and identifying potential therapeutic avenues [165].
Artificial intelligence (AI) and machine learning (ML) are poised to catalyze drug
discovery by analyzing vast genomic datasets, identifying patterns, and predicting inter-
actions, leading to more efficient target identification and drug design. Microbiome-
Table 11.2 (continued)
Genomic technique Advantages Disadvantages Challenges References
Methylation
sequencing (methyl-
Seq)
Maps DNA
methylation patterns.
Identifies
differentially
methylated regions
(DMRs).
Requires bisulfite
conversion, which can
lead to DNA
degradation.
May not distinguish
between DNA
modifications.
Accurate
quantification of
DNA methylation
levels.
Integration with
gene expression
and phenotype
data.
[]
Single-cell
sequencing
Provides insights into
cellular
heterogeneity.
Characterizes rare cell
types and states.
Limited sensitivity and
higher technical noise.
Data analysis
challenges due to
sparse data.
Standardization of
protocols for
consistent results.
Integration of
single-cell data with
bulk data.
[]
11 Role of structural genomics in drug discovery 271
https://t.me/med1917
based therapeutics, capitalizing on genomics to understand microbial communities and
their impact on health, are a burgeoning area with potential implications for drug re-
sponses and toxicities. Rare diseases stand to benefit from genomics-driven insights, as
the identification of genetic causes facilitates targeted therapies and personalized ap-
proaches [166].
The exploration of epigenomics and epitranscriptomics reveals the intricate regu-
latory mechanisms of gene expression, offering new druggable targets and avenues
for epigenetic therapies. Moreover, global collaborations and data sharing initiatives
amplify the potential of genomics research, fostering open-access databases and
shared resources that accelerate advancements and catalyze breakthroughs world-
wide. As these future prospects unfold, the integration of genomics with cutting-edge
technologies, computational prowess, and interdisciplinary approaches will undoubt-
edly reshape the landscape of drug discovery, ushering in an era of more precise, ef-
fective, and personalized therapeutics across diverse disease contexts [167, 168].
11.18 Integration of machine learning and artificial
intelligence in structural genomics
The integration of ML and AI in structural genomics has significantly transformed the
field, enhancing our understanding of protein structures, functions, and interactions.
This convergence of advanced computational techniques with structural biology has
opened up new avenues for predicting, analyzing, and utilizing structural information
[169, 170]. Here’s an explanation of how AI and ML are integrated into structural geno-
mics with the current perspective:
Prediction of protein structures: AI and ML algorithms have been employed to pre-
dict protein structures from amino acid sequences. These methods, known as protein
structure prediction, use large databases of known structures and sequence-structure
relationships to generate accurate 3D models. Deep learning methods, such as recur-
rent neural networks and convolutional neural networks, have shown promise in im-
proving the accuracy of structure predictions by capturing complex patterns in
protein sequences [171].
Structure refinement and validation: AI-driven approaches aid in refining and vali-
dating predicted or experimentally determined structures. These methods use physi-
cal principles, energy minimization algorithms, and statistical potentials to optimize
protein models for better agreement with experimental data. By integrating various
validation metrics and considering stereochemistry, ML algorithms help assess the
quality and reliability of structural models [172, 173].
272 Anuradha Mehra et al.
https://t.me/med1917
Protein–ligand interaction prediction: AI and ML play a crucial role in predicting
protein–ligand interactions, which is vital for drug discovery. Virtual screening meth-
ods employ ML models to predict ligand binding affinities and interactions with target
proteins. These techniques aid in identifying potential drug candidates and optimizing
lead compounds for therapeutic purposes [174].
Function annotation and protein design: ML algorithms assist in annotating protein
functions based on structural features, sequence motifs, and evolutionary relation-
ships. Additionally, AI-guided protein design involves generating novel protein sequen-
ces that fold into desired structures. This has applications in enzyme engineering, drug
delivery, and synthetic biology [175].
Biological network analysis: Integrating structural information with biological net-
works enhances our understanding of cellular processes. AI-driven network analysis pre-
dicts protein–protein interactions, signaling pathways, and functional modules. This aids
in deciphering the roles of individual proteins within larger biological contexts [176].
Data-driven drug discovery: AI and ML accelerate drug discovery by analyzing mas-
sive datasets, predicting drug–target interactions, and identifying potential off-target
effects. This expedites the ident ification of lead compounds and aids in repurposing
existing drugs for new indications [177].
11.18.1 Current perspective
The current perspective of AI and ML in structural genomics is one of rapid advance-
ment and innovation. Researchers are developing novel algorithms that leverage
deep learning architectures to tackle complex challenges in predicting protein struc-
tures, interactions, and functions. These methods are becoming increasingly accurate
and efficient, enabling high-throughput analyses of large protein datasets [178].
AI-driven tools are being integrated into established structural biology pipelines
to enhance data processing, validation, and interpretation. The combination of AI
with experimental techniques like cryo-EM has enabled high-resolution structure de-
termination of challenging macromolecules [179].
Collaborations between structural biologists, computational scientists, and ML ex-
perts are fostering interdisciplinary research, leading to the development of user-
friendly software tools and platforms that democratize AI and ML techniques for
structural genomics researchers.
The integration of AI and ML in structural genomics holds immense potential
for accelerating discoveries, i mproving structural predictions, and driving ad-
vancements in drug discovery. As these technologies continue to evolve, they are
reshaping the landscape of structural biology by enabling more accurate, efficient,
and data-driven approaches [180, 181].
11 Role of structural genomics in drug discovery 273
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана